Browse the corpus

REFERENCES Duvic M, Hymes K, Heald P, et al, “Bexarotene is Effective and Safe for Treatment of Refractory Advanced-Stage Cutaneous T-Cell Lymphoma: Multinational Phase II-III Trial Results,” J Clin Oncol , 2001, 19(9):2456-71. [PubMed 11331325 ] Foss F, Demierre MF, and DiVenuti F, “A Phase-1 Trial of Bexarotene and Denileukin Diftitox in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma,” Blood , 2005, 106(2):454-7. [PubMed 15811959 ] Hamnvik OP, Larsen PR, and Marqusee E, “Thyroid Dysfunction From Antineoplastic Agents,” J Natl Cancer Inst , 2011, 103(21):1572-87. [PubMed 22010182 ] McGinnis KS, Shapiro M, Vittorio CC, et al, “Psoralen Plus Long-Wave UV-A (PUVA) and Bexarotene Therapy: An Effective and Synergistic Combined Adjunct to Therapy for Patients With Advanced Cutaneous T-Cell Lymphoma,” Arch Dermatol , 2003, 139(6):771-5. [PubMed 12810509 ] National Institute for Occupational Safety and Health (NIOSH), "NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012." Available at file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf . Accessed January 21, 2013. Rupoli S, Pimpinelli N, Goteri G, et al, “Low Dose Bexarotene and Ultraviolet A Photochemotherapy (PUVA) in a Prospective Phase II Clinical Study for Refractory and/or Resistant Cutaneous T Cell Lymphomas (CTCL),” Blood , 2010, 116:3953 [abstract 3953 from 2010 ASH Annual Meeting]. Singh F and Lebwohl MG, “Cutaneous T-cell Lymphoma Treatment Using Bexarotene and PUVA: A Case Series,” J Am Acad Dermatol , 2004, 51(4):570-3. [PubMed 15389192 ] Topic 8996 Version 48.0 © 2013 UpToDate, Inc. All rights reserved. | Subscription and License Agreement | Release: 21.6- C21.56 Licensed to: AsanBook Dig. Med. Lib. | Support Tag: [0503-61.234.146.186-11633CD92E-S244013.14]